Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

1(25%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

25%

Ph phase_2

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

3(75.0%)

Phase 3Large-scale testing

1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Detailed Status

Completed3

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 23 (75.0%)

Phase 31 (25.0%)

Trials by Status

completed375%

recruiting125%

Recent Activity

1 active trials

Showing 4 of 4

recruitingphase_2

Intravesical Gem/Doce in Patients With NMIBC

NCT05644041

completedphase_2

Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma

NCT02249702

completedphase_2

Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST

NCT00359333

completedphase_3

Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine

NCT00294385

Clinical Trials (4)

Showing 4 of 4 trials

NCT05644041Phase 2

Intravesical Gem/Doce in Patients With NMIBC

Recruiting

NCT02249702Phase 2

Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma

Completed

NCT00359333Phase 2

Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST

Completed

NCT00294385Phase 3

Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4